ATE545423T1 - Mittel zur behandlung von lungenkrebs - Google Patents

Mittel zur behandlung von lungenkrebs

Info

Publication number: ATE545423T1
Authority: AT; Austria
Prior art keywords: lung cancer; agents; treatment; medicaments; treating
Prior art date: 2002-03-18

Application number

AT03712731T

Other languages

English (en)

Inventor

Toshihiro Noguchi

Akemi Baba

Original Assignee

Dainippon Sumitomo Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-18

Filing date

2003-03-17

Publication date

2012-03-15

2003-03-17 Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co

2012-03-15 Application granted granted Critical

2012-03-15 Publication of ATE545423T1 publication Critical patent/ATE545423T1/de

Links

206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 5
201000005202 lung cancer Diseases 0.000 title abstract 5
208000020816 lung neoplasm Diseases 0.000 title abstract 5
239000003814 drug Substances 0.000 abstract 3
VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 abstract 1
229960002550 amrubicin Drugs 0.000 abstract 1
230000000259 anti-tumor effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
229960005277 gemcitabine Drugs 0.000 abstract 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
229960004768 irinotecan Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 abstract 1
229960002066 vinorelbine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT03712731T 2002-03-18 2003-03-17 Mittel zur behandlung von lungenkrebs ATE545423T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002074962		2002-03-18
PCT/JP2003/003206 WO2003077932A1 (en)	2002-03-18	2003-03-17	Remedies for lung cancer

Publications (1)

Publication Number	Publication Date
ATE545423T1 true ATE545423T1 (de)	2012-03-15

Family

ID=28035342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03712731T ATE545423T1 (de)	2002-03-18	2003-03-17	Mittel zur behandlung von lungenkrebs

Country Status (10)

Country	Link
US (1)	US7091189B2 (de)
EP (1)	EP1488795B1 (de)
JP (2)	JP4786871B2 (de)
KR (1)	KR100978705B1 (de)
CN (2)	CN100400046C (de)
AT (1)	ATE545423T1 (de)
AU (1)	AU2003221036A1 (de)
DK (1)	DK1488795T3 (de)
ES (1)	ES2381408T3 (de)
WO (1)	WO2003077932A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
USRE46708E1 (en)	2002-03-06	2018-02-13	John C. Karamanos	Embedded heat exchanger for heating, ventilation, and air conditioning (HVAC) systems and methods
US11841159B2 (en)	2002-03-06	2023-12-12	John Chris Karamanos	Embedded heat exchanger with support mechanism
ATE545423T1 (de)	2002-03-18	2012-03-15	Dainippon Sumitomo Pharma Co	Mittel zur behandlung von lungenkrebs
CN100438913C (zh) *	2004-11-22	2008-12-03	山东蓝金生物工程有限公司	一种抗癌药物组合物
CA2711802C (en)	2007-01-10	2016-08-16	John C. Karamanos	Embedded heat exchanger for heating, ventilation, and air conditioning (hvac) systems and methods
US8822153B2 (en) *	2007-06-01	2014-09-02	The University Of North Carolina At Chapel Hill	Molecular diagnosis and typing of lung cancer variants
WO2009099649A1 (en) *	2008-02-08	2009-08-13	Poniard Pharmaceuticals, Inc.	Use of picoplatin and bevacizumab to treat colorectal cancer
CN109453195B (zh) *	2018-11-29	2021-04-20	湖南补天药业股份有限公司	一种用于抑制肿瘤细胞的药物组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4315851A (en) *	1978-12-29	1982-02-16	Kureha Kagaku Kogyo Kabushiki Kaisha	Pharmaceutical composition having antitumor activity
US5330744A (en) *	1988-11-14	1994-07-19	Sloan-Kettering Institute For Cancer Research	Method for increasing sensitivity to chemically induced terminal differentiation
US6747055B1 (en) *	1998-07-17	2004-06-08	The United States Of America As Represented By The Department Of Health And Human Services	Water-soluble drugs and methods for their production
TWI317285B (en) *	2000-07-28	2009-11-21	Dainippon Sumitomo Pharma Co	New use and kit for remedies for cancer
US6544962B1 (en) *	2000-11-02	2003-04-08	Matrix Pharmaceutical, Inc.	Methods for treating cellular proliferative disorders
JP5009483B2 (ja)	2001-01-30	2012-08-22	大日本住友製薬株式会社	肺癌治療剤
ATE545423T1 (de) *	2002-03-18	2012-03-15	Dainippon Sumitomo Pharma Co	Mittel zur behandlung von lungenkrebs

2003
- 2003-03-17 AT AT03712731T patent/ATE545423T1/de active
- 2003-03-17 CN CNB038113473A patent/CN100400046C/zh not_active Expired - Fee Related
- 2003-03-17 WO PCT/JP2003/003206 patent/WO2003077932A1/ja not_active Ceased
- 2003-03-17 EP EP03712731A patent/EP1488795B1/de not_active Expired - Lifetime
- 2003-03-17 ES ES03712731T patent/ES2381408T3/es not_active Expired - Lifetime
- 2003-03-17 DK DK03712731.3T patent/DK1488795T3/da active
- 2003-03-17 AU AU2003221036A patent/AU2003221036A1/en not_active Abandoned
- 2003-03-17 JP JP2003575985A patent/JP4786871B2/ja not_active Expired - Lifetime
- 2003-03-17 KR KR1020047014610A patent/KR100978705B1/ko not_active Expired - Fee Related
- 2003-03-17 US US10/508,025 patent/US7091189B2/en not_active Expired - Fee Related
- 2003-03-17 CN CN2007101966777A patent/CN101185652B/zh not_active Expired - Fee Related
2011
- 2011-05-31 JP JP2011122274A patent/JP2011168621A/ja active Pending

Also Published As

Publication number	Publication date
EP1488795B1 (de)	2012-02-15
CN1652800A (zh)	2005-08-10
KR20040097178A (ko)	2004-11-17
JPWO2003077932A1 (ja)	2005-07-14
EP1488795A4 (de)	2007-07-25
CN101185652A (zh)	2008-05-28
ES2381408T3 (es)	2012-05-28
JP4786871B2 (ja)	2011-10-05
EP1488795A1 (de)	2004-12-22
DK1488795T3 (da)	2012-05-07
AU2003221036A1 (en)	2003-09-29
JP2011168621A (ja)	2011-09-01
WO2003077932A1 (en)	2003-09-25
KR100978705B1 (ko)	2010-08-30
CN101185652B (zh)	2010-12-08
US20050119196A1 (en)	2005-06-02
US7091189B2 (en)	2006-08-15
CN100400046C (zh)	2008-07-09

Publication	Publication Date	Title
DE60222137D1 (de)	2007-10-11	Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
TW200518752A (en)	2005-06-16	Combinations of drugs for the treatment of neoplasms
BR0312597A (pt)	2005-05-10	Combinações de drogas para o tratamento de neoplasmas
ATE307608T1 (de)	2005-11-15	Kombination von doctaxel und rhumab her2 zür krebsbehandlung
ATE399553T1 (de)	2008-07-15	Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
BR0313282A (pt)	2005-10-18	Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia
MXPA03008623A (es)	2004-05-21	Combinacion farmaceutica para el tratamiento del cancer.
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
DE602004028841D1 (de)	2010-10-07	Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
DE50311898D1 (de)	2009-10-22	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
IL171607A (en)	2016-05-31	Use of botulinum toxin for the treatment of sinusitis-induced headaches
MX337511B (es)	2016-03-09	Medicamentos y metodos para tratar cefaleas.
DE60324427D1 (de)	2008-12-11	Verfahren zur modulation der tubulindeacetylase-aktivität
WO2003092617A3 (en)	2004-05-13	Combinations for the treatment of inflammatory skin disorders
MXPA05004697A (es)	2005-10-18	Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
ATE543492T1 (de)	2012-02-15	Behandlung von lungenkrebs
EA200970345A1 (ru)	2009-10-30	Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
DK1689404T3 (da)	2009-01-26	Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2005011572A3 (en)	2005-03-10	Combination of drugs for the treatment of neoplasms
ATE545423T1 (de)	2012-03-15	Mittel zur behandlung von lungenkrebs
WO2004007676A3 (en)	2004-04-08	Combination therapy for the treatment of neoplasms
TW200510437A (en)	2005-03-16	Phosphinane compound with immunomodulating activity
BR9908190A (pt)	2000-10-24	Processos para tratar a dor especìfica de fêmea em um paciente fêmea, e para tratar a dor crÈnica em um paciente
ATE345805T1 (de)	2006-12-15	Calciumtrifluoracetat mit zytotoxischer wirkung
EA200600989A1 (ru)	2006-10-27	Применение габоксадола для лечения бессонницы